Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Biomarkers of Cognitive Impairment: Brain Cortical Thickness, Volumetrics, and Cerebrospinal Fluid

Ghazi-Saidi, Ladan, PhD*; Walsh, Ryan R., MD, PhD; Shan, Guogen, PhD‡,§; Banks, Sarah J., PhD§ for the Alzheimer’s Disease Neuroimaging Initiative

Alzheimer Disease & Associated Disorders: July-September 2018 - Volume 32 - Issue 3 - p 255–257
doi: 10.1097/WAD.0000000000000226
Brief Reports

*Department of Communication Disorders, College of Education, University of Nebraska at Kearney, Kearney, NE

Muhammad Ali Parkinson Center, Barrow Neurological Institute, Phoenix, AZ

School of Community Health Sciences, University of Nevada Las Vegas

§Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV

Supported by grant funding from the National Institute of General Medical Sciences (grant: P20GM109025). Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). For up-to-date information, see www.adni-info.org. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc.; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co. Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California.As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

The authors declare no conflicts of interest.

Reprints: Sarah J. Banks, PhD, Cleveland Clinic Lou Ruvo Center for Brain Health, 888 W Bonneville, Las Vegas, NV 89106 (e-mail: bankss2@ccf.org).

Received June 6, 2017

Accepted October 2, 2017

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved